Skip to main content
. 2024 Oct 22;134(24):e180282. doi: 10.1172/JCI180282

Figure 4. Siglec-7 ligand and Siglec-9 ligand are expressed in PCa cells.

Figure 4

(A) The expression levels of Siglec-7 ligand (Siglec-7L) and Siglec-9L, and (B and C) their corresponding quantification by MFI by flow cytometry. (D) Confocal microscopy analysis of PC3 PCa cells showing cell surface–associated expression patterns of Siglec-7 and Siglec-9. Treatment with sialidase abolishes the binding of Siglec-7-Fc and Siglec-9-Fc proteins visualized by confocal microscopy, indicating dependence on sialic acid. (E) Representative IHC analysis of Siglec-7 and Siglec-9 ligand expression in PCa tumor tissues. High expression levels of Siglec-7 and Siglec-9 ligands are observed in tumor tissues from patients with PCa, while normal tissue samples show either absence or low expression levels.Magnification, × 40. (F) Representative Siglec-7 and Siglec-9L expression profile on tumor cells derived from patient tumor tissues by flow cytometry, (G) Expression of Siglec-9L expression profile in all cells from tumor tissue, and adjacent normal tissues (n = 6). Quantification of (H) Siglec-7L and (I) Siglec-9L in samples from patients with PCa, suggesting significant higher expression levels of Siglec-7L and Siglec-9L in tumor tissues compared with adjacent normal tissues. Data were analyzed paired Student’s t test and presented as mean ± SEM.; *P ≤ 0.05; **P ≤ 0.01.